Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Walter in HK who wrote (883)	3/7/1999 7:50:00 PM
From: investor	Read Replies (2) \| Respond to of 1754

one doctor I spoke to is actually short the visx.He feels it's downward from here.Most of their revenue is from the licensing fee each time a doctor does a procedure.That is what is keeping the price high.Notice in Europe and Canada the price is cheaper due to no royalty on each procedure.N iCad does not have a royalty fee.What laser do you think they'll prefer?Their also is a private placement being done by one of the premierlaser doctors.He too has stated that his deal will use the Nicad laser.Alsonote that visx has already lost two patent suits in europe. What other good news could be forthcoming to justify a 40 point move?